LT2049148T - Žmogaus augimo hormono skysta stabili kompozicija - Google Patents

Žmogaus augimo hormono skysta stabili kompozicija

Info

Publication number
LT2049148T
LT2049148T LTEP06769186.5T LT06769186T LT2049148T LT 2049148 T LT2049148 T LT 2049148T LT 06769186 T LT06769186 T LT 06769186T LT 2049148 T LT2049148 T LT 2049148T
Authority
LT
Lithuania
Prior art keywords
growth hormone
liquid formulation
human growth
stable liquid
stable
Prior art date
Application number
LTEP06769186.5T
Other languages
English (en)
Inventor
Sun Hee Kim
Yo Kyung Chung
Jae Young Chang
Sang Kil Lee
Min Suk Lee
Seung Kook Park
Original Assignee
Daewoong Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Co., Ltd. filed Critical Daewoong Co., Ltd.
Publication of LT2049148T publication Critical patent/LT2049148T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP06769186.5T 2006-07-06 2006-07-06 Žmogaus augimo hormono skysta stabili kompozicija LT2049148T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2006/002640 WO2008004717A1 (en) 2006-07-06 2006-07-06 A stable liquid formulation of human growth hormone

Publications (1)

Publication Number Publication Date
LT2049148T true LT2049148T (lt) 2016-11-25

Family

ID=38894670

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP06769186.5T LT2049148T (lt) 2006-07-06 2006-07-06 Žmogaus augimo hormono skysta stabili kompozicija

Country Status (11)

Country Link
US (1) US8409586B2 (lt)
EP (1) EP2049148B1 (lt)
JP (1) JP5180202B2 (lt)
CN (1) CN101505789A (lt)
BR (1) BRPI0621841B8 (lt)
ES (1) ES2605022T3 (lt)
HK (1) HK1216992A1 (lt)
HU (1) HUE031329T2 (lt)
LT (1) LT2049148T (lt)
PT (1) PT2049148T (lt)
WO (1) WO2008004717A1 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc eMIPを有効成分とする水溶性製剤
RU2558821C2 (ru) * 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
HK1223559A1 (zh) * 2013-11-12 2017-08-04 Cadila Healthcare Limited 用於促性腺激素的配方
US9908976B2 (en) 2015-03-18 2018-03-06 Psmg, Llc Stable polyethylene glycol particle dispersions and methods for forming the stable dispersions
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61296598A (ja) 1985-06-21 1986-12-27 Mitsubishi Electric Corp Mosダイナミツクramのダミ−ワ−ド線駆動回路
EP0303746B2 (en) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DK0955062T3 (da) 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
KR970006498A (ko) 1995-07-31 1997-02-21 유충식 활성형 인성장호르몬의 정제 방법
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
KR100210840B1 (ko) 1996-12-24 1999-07-15 구본준 기계 화학적 연마 방법 및 그 장치
KR19990001217A (ko) 1997-06-13 1999-01-15 윤종용 스탠바이 모드에서의 시스템 구동방법 및 장치
JP3723857B2 (ja) 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
KR100573704B1 (ko) 1998-12-02 2006-07-21 동아제약주식회사 인성장 호르몬의 안정화된 액상제제_
CZ305123B6 (cs) * 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
MXPA02003540A (es) 1999-10-08 2003-09-12 Nektar Therapeutics Al Corp Derivados de poli(etilenglicol) heterobifuncionales y los metodos para su preparacion.
MXPA03000073A (es) * 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
AU2003249992A1 (en) * 2002-07-09 2004-01-23 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20060252682A1 (en) * 2003-03-18 2006-11-09 Ares Trading S.A. Liquid growth hormone formulation and process of preparation thereof
KR100537260B1 (ko) 2003-09-03 2005-12-19 한미약품 주식회사 인간 성장 호르몬의 안정화된 액상 제제용 조성물
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
WO2005027960A1 (en) 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
DE10355189B4 (de) * 2003-11-26 2015-04-30 Johnson & Johnson Medical Gmbh Verfahren zum Herstellen eines chirurgischen Implantats sowie chirurgisches Implantat
JP4845741B2 (ja) * 2003-12-23 2011-12-28 ファルマシア コーポレーション 安定な成長ホルモン液体製剤

Also Published As

Publication number Publication date
JP2009542629A (ja) 2009-12-03
ES2605022T3 (es) 2017-03-10
BRPI0621841A2 (pt) 2011-12-20
BRPI0621841B8 (pt) 2021-05-25
HK1216992A1 (zh) 2016-12-16
EP2049148A4 (en) 2013-12-11
EP2049148B1 (en) 2016-09-28
HUE031329T2 (hu) 2017-07-28
US20090298768A1 (en) 2009-12-03
PT2049148T (pt) 2016-12-30
CN101505789A (zh) 2009-08-12
WO2008004717A1 (en) 2008-01-10
US8409586B2 (en) 2013-04-02
BRPI0621841B1 (pt) 2020-12-29
WO2008004717A9 (en) 2013-08-29
EP2049148A1 (en) 2009-04-22
JP5180202B2 (ja) 2013-04-10

Similar Documents

Publication Publication Date Title
IL224225B (en) Liquid formulation of long-acting human growth hormone conjugate
ZA200904544B (en) Stable S-(+)-abscisic acid liquid and soluble granule formulations
EP2081502B8 (en) A medical device for attaching tissue to bone
EP1942981A4 (en) DISTRIBUTION OF MEDIUM TO TISSUE
ZA200900345B (en) Preparation of pharmaceutical formulations
PT1986606T (pt) Formulações líquidas contendo fenilefrina
IL220465A0 (en) Methods and compositions for stable liquid drug formulations
GB201010796D0 (en) Improvements relating to medical devices
IL181348A0 (en) Liquid preparation of physiologically active peptide
ZA200900125B (en) Liquid formulation of pyrethroids
ZA200908962B (en) A liquid formulation for administering nicotine
PL1570866T3 (pl) Sposób dostarczania płynnego środka sterylizującego do sterylizatora
IL195034A0 (en) Liquid pharmaceutical formulation
GB0614586D0 (en) Pharmaceutical Formulation
IL209698A (en) Use of Niportimox for the preparation of pharmaceuticals and preparations containing this Niportimox
HUE031329T2 (hu) Humán növekedési hormon stabil folyékony készítménye
PL2054028T3 (pl) Podskórne implanty uwalniające aktywny składnik przez przedłużony okres czasu
IL213711A (en) Nano-phenofibrate preparation
ZA200704926B (en) Modified human growth hormone
EP2073631A4 (en) AGROCHEMICAL FORMULATIONS OF LIQUID CRYSTALS
IL197033A0 (en) Single use self-disabling syringe
IL199756A0 (en) Medically active plaster
GB0813004D0 (en) Stable therapeutic formulation of human growth hormone
GB2451360B (en) Hormone replacement formulation
HK1136977A (en) Human growth hormone formulations